Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase IIa Multicenter Double Blind Study to Evaluate the Efficacy and Safety of Low Doses of Oral NT-KO-003 for the Treatment of Multiple Sclerosis

NCT01428726 is registered in ClinicalTrials.gov with Neurotec Pharma as lead sponsor.

NCT NCT01428726
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01428726 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase IIa Multicenter Double Blind Study to Evaluate the Efficacy and Safety of Low Doses of Oral NT-KO-003 for the Treatment of Multiple Sclerosis
Lead sponsor
Neurotec Pharma
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2011
Completion date
January 31, 2014
Enrollment
99 (estimated)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

relapsing remitting multiple sclerosis